CombinatoRx News

Biotechnology developer CombinatoRx Inc. has completed its merger with Canada's Neuromed Pharmaceuticals .

CombinatoRx, Incorporated announced that preclinical data from its Adenosine A2A receptor and Beta-2 Adrenergic Receptor Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.

CombinatoRx, Incorporated today announced that two abstracts highlighting data on its A2A and Beta-2 Adrenergic Receptor Agonist oncology programs have been accepted for presentation at the American Society for Hematology 2009 Annual Meeting in New Orleans on December 5-8, 2009.

CAMBRIDGE, Mass. & VANCOUVER, British Columbia-- --CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration has issued Neuromed a letter extending its review of the New Drug Application for the product candidate Exalgo extended-release tablets ...

Several stocks trading under $5 were poised to move on above-average volume during Monday's session.

CombinatoRx Inc. shares fell 46 percent after US regulators rejected an application for the experimental painkiller Exalgo.

CombinatoRx, Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released 2009-11-16 02:35:20 - CombinatoRx, Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com www.companiesandmarkets.com/Summary-Company-Profile/combinatorx, ..

Several small-cap stocks were poised to move on above-average volume during Wednesday's session Novavax rose by 7 cents, or 1.8%, to $3.92 in the premarket session after the company said it has entered into a strategic collaboration with Xcellerex to develop a large-scale manufacturing process for its 2009 H1N1 influenza VLP vaccine.

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis Phase 2 extension trial for Synavivea at the American College of Rheumatology 2009 Annual Meeting in Philadelphia.

CombinatoRx, Incorporated today announced that its abstract entitled, a oeCRx-102 Enhances Glucocorticoid Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Resultsa , has been accepted for oral presentation at the American College of Rheumatology 2009 Annual Meeting in Philadelphia on October 20, 2009.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Cambridge-based CombinatoRx Inc. said yesterday that its development partner, Fovea Pharmaceuticals, may be acquired by the French drug maker Sanofi-Aventis. CombinatoRx and Fovea are working together on the drug candidate Prednisporin, which is intended to treat persistent allergic conjunctivitis.

On 5/26/09, Johnson & Johnson announced that the FDA extended by three months the review timeline for the Biologic License Application for Stelara to provide time for a full review of an amendment to the pending application.

Drug developer CombinatoRx Inc. said Nasdaq Stock Market Officials have halted trading of the company's common shares pending a regulatory review of the company's new drug application for its Exalgo pain medication.

CombinatoRx, Incorporated and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration has posted on its website briefing documents for the September 23, 2009 joint meeting of its Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management ...

A subsidiary of Clinical Data Inc. and CombinatoRx Inc. have signed a licensing agreement valued at up to $257 million in milestone and royalty payments.

Clinical Data Inc. entered a collaboration and licensing agreement with CombinatoRx Inc.

Clinical Data Inc. said Thursday it licensed a potential cancer treatment to CombinatoRx in a deal worth as much as $252 million, plus royalties on sales.

CombinatoRx, a cash-strapped Cambridge-based biotechnology company, announced it swung to profitability in the second quarter, due to dramatic cost cuts, discontinued operations and new collaborations.

CombinatoRx, a cash-strapped Cambridge-based biotechnology company, announced it swung to profitability in the second quarter, due to dramatic cost cuts, discontinued operations and new collaborations.